Key statistics dashboard for PolyPid Ltd. (PYPD). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials.
Stock Data
| Price | $5.21 |
| Market Cap | $99M |
| Beta | 1.46 |
| Exchange | NASDAQ |
| Country | IL |
Valuation Multiples
| P/E Ratio | -3.46 |
| Price / Book | 21.49 |
| P/S | 0.00 |
| P/FCF | 0.00 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 1.35 |
| Quick Ratio | 1.14 |
| Cash Ratio | 0.99 |
| Debt / Equity | 0.29 |
| Debt / Assets | 10.32% |
| Interest Coverage | 48.50 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 0.24 |
| Cash per share | 0.29 |
| FCF per share | 0.00 |
| Tangible Book Value per share | 0.24 |
| Dividend per share | 0.00 |
Related companies: ANVS · ATNM · BCAB · BTAI · CELU · EVAX · MAIA
Explore sector: Healthcare · Biotechnology
More sections of PYPD: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks